Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen
Open Access
- 1 January 2010
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 49 (3) , 305-312
Abstract
Background. Up to one-quarter of breast cancer patients suffer clinically significant depression in the year after diagnosis, which may respond to intervention. About half may be prescribed a psychotropic medication, such as a selective serotonin reuptake inhibitor (SSRI), while completing breast cancer therapy. Cytochrome P-450 2D6 (CYP2D6) metabolizes SSRIs and also metabolizes tamoxifen to more active forms. Therefore, concurrent use of SSRIs may reduce tamoxifen’s effectiveness at preventing breast cancer recurrence. The SSRI citalopram has limited potency to inhibit CYP2D6 activity, so has been recommended for breast cancer patients taking tamoxifen. This study provides epidemiologic evidence to support this recommendation. Material and methods. We conducted a case-control study of breast cancer recurrence nested in the population of female residents of Denmark who were diagnosed with non-metastatic estrogen-receptor positive breast cancers between 1994 and 2001 and who took tamoxifen for at least one year. We ascertained complete prescription histories by linking cases’ and controls’ civil registration numbers to the Danish national prescription registry. We estimated the association between SSRI use while taking tamoxifen and risk of recurrent breast cancer. Results. About the same proportion of recurrent cases (37 of 366) and matched controls (35 of 366) received at least one prescription for citalopram or its s-stereoisomer while taking tamoxifen (adjusted odds ratio = 1.1, 95% confidence interval = 0.7, 1.7). Breast cancer patients taking other SSRIs were also at no increased risk of recurrence (adjusted odds ratio = 0.9, 95% confidence interval = 0.5, 1.8). Discussion. Breast cancer patients with indications for an SSRI may be prescribed citalopram – and possibly other SSRI – without adversely affecting the outcome of adjuvant therapy with tamoxifen.Keywords
This publication has 27 references indexed in Scilit:
- No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting MedicationsCancer Epidemiology, Biomarkers & Prevention, 2009
- Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.JNCI: Journal of the National Cancer Institute, 2004
- Distress, psychiatric morbidity, and prescriptions for psychotropic medication in a breast cancer waiting room sampleGeneral Hospital Psychiatry, 2004
- A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic BiomarkersJNCI: Journal of the National Cancer Institute, 2003
- Efficacy of Citalopram as a Monotherapy or as an Adjunctive Treatment to Estrogen Therapy for Perimenopausal and Postmenopausal Women With Depression and Vasomotor SymptomsThe Journal of Clinical Psychiatry, 2003
- Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.2001
- Biologic Activity of Tamoxifen at Low Doses in Healthy WomenJNCI: Journal of the National Cancer Institute, 1998
- Variable contribution of cytochromes p450 2d6, 2c9 and 3a4 to the 4-hydroxylation of tamoxifen by human liver microsomesBiochemical Pharmacology, 1997
- Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetineEuropean Journal of Clinical Pharmacology, 1996
- IDENTIFICATION OF 4-HYDROXY-N-DESMETHYLTAMOXIFEN AS A METABOLITE OF TAMOXIFEN IN HUMAN BILE1988